ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

Celgene Signs CRADA With NCI For Development Of CDC-501.

June 30, 2000

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012

Bush Budget Proposal a $511 Million Cut For NIH.

February 9, 2007

Study Finds Short Term Tests Predict Carcinogenicity

April 25, 1980

Pediatric Oncology Groups Plan To Merge, Citing Greater Cost Efficiencies, Leverage

August 7, 1998

DCPC advisors OK 16 Year Trial Of Screening Methods

February 15, 1991